info, page-2

VH
There's always possibility with PNO. It has been a day traders dream, which makes it very volatile, and when it 'goes' it really goes!
But on a positive side for the real story, you have to decide what the potential of product is.


PHARMANET GROUP LIMITED
REGISTERED OFFICE
Level 1, 284 Oxford Street
Leederville, WA 6007
AUSTRALIA
+61 8 9242 2999
13 July 2004
FOR IMMEDIATE RELEASE
NEW DISCOVERY - TRIPEPTOFEN
================================
PharmaNet Group Ltd (ASX PNO) today announced significant results from the
first stage of the comprehensive investigation into the company’s nutracel protein
technology. A previously undiscovered pain-killing compound was identified and
named “Tripeptofen”.
The scientific team believes the compound (Tripeptofen) has significant
international medical and commercial importance.
Tripeptofen, is a new fast-acting and effective anti-pain compound with low drug
interactivity ideally suited to the needs of the sporting and aging markets.
PharmaNet’s medical products had previously been confined to the anti-arthritic
and anti-inflammatory fields, however the discovery of Tripeptofen as a new
peptide-based analgesic compound will open commercial opportunities for the
company in the international pharmaceutic ingredients sector.
Tripeptofen has a similar structure to a number of naturally occurring peptide painkillers,
however the proprietary manufacturing process used to create Tripeptofen is
far more suited to commercial production than other peptide production methods.
Cambridge Scientific Pty Ltd, a wholly owned subsidiary of PharmaNet Group has
lodged a Patent Application and holds the intellectual property.
PharmaNet continues to review all commercial and corporate options in the
development and commercialisation of this new opportunity in order to maximise
shareholder value.
- Ends -